The role of thyroid-stimulating hormone and thyroglobulin antibody in abnormally invasive placenta

被引:4
|
作者
Ozler, Sibel [1 ]
Oztas, Efser [2 ]
Kebapcilar, Aysegul [3 ]
Caglar, Ali Turhan [4 ]
机构
[1] Selcuk Univ, Fac Med, Perinatol, TR-42050 Konya, Turkey
[2] Kutahya Univ Hlth Sci, Perinatol, Kutahya, Turkey
[3] Selcuk Univ, Fac Med, Obstet & Gynecol, Konya, Turkey
[4] TC Saglik Bakanligi Ankara Sehir Hastanesi, Perinatol, Ankara, Turkey
来源
关键词
Thyroid-stimulating antibody; thyroglobulin antibody; placenta accreta spectrum; cesarean hysterectomy; massive blood transfusion;
D O I
10.1080/14767058.2021.1875430
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose: Thyroid hormones and antibodies are known to participate in angiogenesis and invasion and also thyroid hormone receptors are expressed in the placenta. We aimed to evaluate the relationship of serum levels of thyroid-stimulating hormone (TSH), thyroid hormones (TH), and anti-thyroid antibodies with abnormally invasive placenta (AIP). We also aimed to investigate whether they are related with cesarean hysterectomy and massive blood transfusion need in AIP cases. Methods: A total of 88 pregnant patients were enrolled in this prospective case-control study (30 with AIP, 28 with non-adherent placenta previa totalis (PPT) and 30 controls). Serum TSH, thyroid hormone [T3 (triiodothyronine) and T4 (thyroxine)] and thyroid antibodies against thyroglobulin (TgAb) and thyroid peroxidase (TPOAb) levels were studied in maternal serum at initial admission to our Perinatology Unit (at early third trimester). The factors associated with increased risk of AIP, cesarean hysterectomy, massive blood transfusion, and adverse perinatal outcomes were evaluated with multiple logistic regression analysis. Adjusted odds ratios and 95% confidence intervals were also calculated. Results: Serum TSH and TgAb levels were significantly lower in the AIP group than both PPT and control groups (p = .01, p < .001 and p < .001, p < .001 respectively). Decreased serum levels of TSH (<2.16 mIU/L) and TgAb (<2.70 mIU/L) levels and high previous cesarean section rates were found to be independently associated with AIP in pregnant women with PPT (OR: 0.4, 95% CI: 0.1-0.9; p = .04, OR: 0.7, 95%CI: 0.4-1.3, p = .02 and OR: 0.1, 95% CI: 0.1-0.5, p = .01). Decreased serum TSH and TgAb levels were found to be independently associated with an increased rate of cesarean hysterectomy and massive blood transfusion in AIP cases (OR: 3.7, 95% CI: 1.4-9.8; p = .01, OR: 1.8, 95% CI: 1.1-3.1; p = .03 and OR: 2.6, 95% CI: 1.0-6.5; p = .05, OR: 2.2, 95% CI: 1.1-4.1 p = .02). Decreased TSH and TgAb serum levels were also found to be independently associated with adverse perinatal outcomes in AIP cases (OR: 3.4, 95% CI: 1.3-11.0; p = .01 and OR: 1.978, 95% CI: 2-3.6; p = .03). Conclusion: Decreased serum TSH and TgAb levels, and previous history of cesarean section were all found to be significantly associated with AIP in cases with PPT. We suggest that maternal serum TSH and TgAb levels can provide additional contribution to obstetric Doppler ultrasound in the diagnosis of AIP and thus can reduce the risks of unplanned cesarean hysterectomy in cases with PPT.
引用
收藏
页码:5108 / 5115
页数:8
相关论文
共 50 条
  • [41] THYROID-STIMULATING AND LIPOLYTIC-ACTIVITIES OF PURIFIED PREPARATIONS OF HUMAN THYROID-STIMULATING HORMONE
    HARTREE, AS
    THOMAS, M
    BURNS, TW
    LANGLEY, P
    FURNIVAL, BE
    [J]. JOURNAL OF ENDOCRINOLOGY, 1972, 53 (01) : 95 - &
  • [42] THYROID-STIMULATING HORMONE - STRUCTURE AND FUNCTION
    MAGNER, JA
    [J]. CONTROL OF THE THYROID GLAND: REGULATION OF ITS NORMAL FUNCTION AND GROWTH, 1989, 261 : 27 - 103
  • [43] Correlation analysis of serum thyroglobulin, thyroid-stimulating hormone levels, and thyroid-cancer risk in thyroid nodule surgery
    Shuai, Jin-Hao
    Leng, Zhao-Fang
    Wang, Peng
    Ji, Yi-Chi
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (27) : 6407 - 6414
  • [44] IMMUNITY TO THE THYROID-STIMULATING HORMONE RECEPTOR
    FURMANIAK, J
    SMITH, BR
    [J]. SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1993, 14 (03): : 309 - 321
  • [45] Thyroid-stimulating hormone pituitary adenomas
    Clarke, Michelle J.
    Erickson, Dana
    Castro, M. Regina
    Atkinson, John L. D.
    [J]. JOURNAL OF NEUROSURGERY, 2008, 109 (01) : 17 - 22
  • [46] PURIFICATION AND CHEMISTRY OF THE THYROID-STIMULATING HORMONE
    PIERCE, JG
    CARSTEN, ME
    WYNSTON, LK
    [J]. ANNALS OF THE NEW YORK ACADEMY OF SCIENCES-SERIES, 1960, 86 (02): : 612 - 624
  • [47] JUVENILE THYROID-STIMULATING HORMONE THYROTOXICOSIS
    MEDINA, A
    HEYMANN, T
    SHENKOLOVSKY, E
    CHOWERS, I
    [J]. ISRAEL JOURNAL OF MEDICAL SCIENCES, 1986, 22 (06): : 500 - 500
  • [48] THYROID-STIMULATING HORMONE LEVEL ELEVATION
    KHARDORI, R
    KHARDORI, N
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1981, 141 (13) : 1847 - 1847
  • [49] THYROID-STIMULATING HORMONE AND ENDEMIC GOITER
    KAJUBI, SK
    [J]. LANCET, 1975, 2 (7924): : 83 - 84
  • [50] Roxadustat and thyroid-stimulating hormone suppression
    Tokuyama, Atsuyuki
    Kadoya, Hiroyuki
    Obata, Atsushi
    Obata, Takahiro
    Sasaki, Tamaki
    Kashihara, Naoki
    [J]. CLINICAL KIDNEY JOURNAL, 2021, 14 (05) : 1472 - 1474